Key facts
- Muna Therapeutics published research in Nature Medicine.
- The study validates microglial state transitions as key drivers of Alzheimer's disease.
- The MiND-MAP platform was used to identify critical tipping points in microglial response.
- Findings support Muna's strategy targeting TREM2 signaling for neuroprotection.
Muna Therapeutics has announced the publication of a study in Nature Medicine that validates microglial state transitions as critical drivers of Alzheimer's disease. The research employed Muna's proprietary MiND-MAP platform to identify key tipping points in the microglial response to amyloid and tau pathology. These findings provide scientific validation for Muna's therapeutic strategy, which focuses on targeting TREM2 signaling to enhance neuroprotection. The company is based in Copenhagen, Denmark, and Boston, USA.